| 发明名称 |
Compounds for the treatment of conditions associated with DGAT1 activity |
| 摘要 |
The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. |
| 申请公布号 |
US9242971(B2) |
申请公布日期 |
2016.01.26 |
| 申请号 |
US201514630624 |
申请日期 |
2015.02.24 |
| 申请人 |
NOVARTIS AG |
发明人 |
Capacci-Daniel Christina;Delacruz Marilyn;Gong Baoqing;Jain Akash;Lu Yansong;Zhang Lijun |
| 分类号 |
C07D413/00;C07D413/12;A61K31/4439;A61K45/06 |
主分类号 |
C07D413/00 |
| 代理机构 |
|
代理人 |
Roth Joshua |
| 主权项 |
1. A crystalline form of the meglumine salt of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid represented by formula (la):wherein the form is Form A characterized in that said form has an X-ray powder diffraction pattern with peaks at degrees two theta (+0.1 degree) selected from 14.008; 15.814; 17.235; 18.629; and 21.893. |
| 地址 |
Basel CH |
